3M CO quarterly report, Q1 FY2024

Full document

3M Company — Q1 2024 Form 10-Q

Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. The April 1, 2024 Solventum separation occurred after quarter-end, so Health Care remained in Q1 results. 3M distributed 80.1% of Solventum to shareholders and retained approximately 19.9%; Solventum results are expected to be reported as discontinued operations from Q2 2024.

Financial performance and liquidity

  • Sales: $8.003 billion, down 0.3% reported; organic sales were flat. Foreign-exchange translation reduced sales by 0.6 percentage points. Americas sales were down 0.5%, Asia Pacific down 3.4%, and EMEA up 4.8%.
  • Profit: Operating income was $1.501 billion, up 21%; operating margin improved to 18.8% from 15.4%. Net income attributable to 3M was $928 million, down 5%; diluted EPS was $1.67 versus $1.76. Adjusted diluted EPS, a non-GAAP measure, was $2.39 versus $1.97.
  • Costs and taxes: Cost of sales fell to 54.1% of revenue from 57.4%, with management citing productivity and stock-compensation timing. The effective tax rate rose to 24.7% from 17.7%, reflecting prior-year tax benefits, lower current-year benefits, and Solventum-related entity-structuring costs. Other expense, net, rose to $264 million from $52 million, including $385 million of interest expense.
  • Segment results: Safety and Industrial sales fell 1.7% to $2.732 billion; operating income rose to $657 million. Transportation and Electronics sales rose 2.6% to $2.104 billion; operating income was $481 million. Health Care sales rose 0.3% to $2.017 billion; operating income fell to $354 million. Consumer sales fell 4.3% to $1.140 billion; operating income rose to $216 million. Segment income comparisons are affected by special items and other non-GAAP adjustments described in the filing.
  • Cash flow: Operating cash flow was $767 million, down from $1.275 billion. Capital expenditures were $375 million; free cash flow, a non-GAAP measure, was $392 million versus $800 million, and free-cash-flow conversion was 42% versus 82%. The company cited a $253 million Combat Arms Earplugs settlement payment and weaker inventory-related cash flow.
  • Liquidity and debt: Cash and cash equivalents were $10.911 billion; cash, cash equivalents, and marketable securities totaled $10.991 billion. Reported total debt was $21.413 billion and reported net debt was $10.422 billion, compared with $10.029 billion at year-end 2023. These quarter-end figures include Solventum borrowings; after the separation, repayment obligations became Solventum’s responsibility. 3M said it expects to retain approximately $7.7 billion of proceeds from those borrowings after transaction accounting is completed. 3M had no commercial paper outstanding at quarter-end.
  • Shareholder returns: Dividends paid were $835 million; the declared quarterly dividend was $1.51 per share. 3M repurchased $21 million of stock during the quarter.

Changes and management commentary

  • Results were mixed across end markets. Management cited electronics demand stabilization, automotive electrification and product launches as growth drivers in Transportation and Electronics; consumer discretionary softness and portfolio prioritization weighed on Consumer. Disposable respirator sales declines and mixed industrial demand affected Safety and Industrial.
  • Management attributed improved operating margins to productivity, restructuring, spending discipline and stock-compensation timing. The timing benefit is not necessarily recurring: the 2024 annual stock award grant was to occur after the Solventum separation.
  • 3M’s 2023–2025 structural reorganization is expected to affect approximately 8,500 positions and incur $700–$900 million in pre-tax charges. Actions committed through Q1 2024 had affected approximately 6,500 positions; Q1 2024 charges were $104 million. Further actions are expected.
  • 3M continues its plan to exit PFAS manufacturing and work to discontinue PFAS use across its product portfolio by the end of 2025. Management noted that third-party substitutes, regulatory approvals and customer requalification could delay or limit transition in some applications.
  • No specific consolidated full-year revenue or EPS guidance is provided in the supplied filing text. Management preliminarily estimated continuing-operations defined-benefit pension and postretirement expense of approximately $190 million for 2024, subject to the separation and plan remeasurement.

Contingencies, unusual items and principal risks

  • PFAS and environmental matters: At March 31, 3M recorded $11.1 billion of “other environmental liabilities,” primarily PFAS-related, including the public water systems settlement; the filing states that loss above recorded accruals cannot currently be estimated. The PWS settlement, approved by the court in March 2024, provides for total payments of $10.5–$12.5 billion from 2023 through 2036, subject to settlement terms and testing outcomes. The quarter’s PFAS-related accrual increase was primarily interest accretion. Regulatory developments, remediation obligations, litigation and potential facility restrictions remain material uncertainties.
  • Combat Arms Earplugs: 3M’s settlement provides for $6.0 billion of contributions through 2029, subject to participation terms. More than 99% of claimants were participating as of the final registration date; the 98% threshold was met. The March 31 accrued liability was $4.8 billion, and 3M paid $350 million on April 15, 2024. The settlement does not admit liability; insurance recovery efforts continue.
  • Respirator and other litigation: The March 31 accrual for non-Aearo respirator mask/asbestos claims was $558 million, with a separate $54 million Aearo accrual. 3M said it cannot estimate potential losses above these accruals. The filing also describes extensive PFAS litigation and regulatory matters, as well as Bair Hugger and other product claims; certain Solventum-related liabilities are allocated to or indemnified by Solventum.
  • Restructuring and PFAS exit costs: Charges and execution costs may continue. Supply availability, customer qualification, permits and regulatory changes could affect costs, operations and product availability.
  • Credit, separation and operating risks: Credit ratings included Moody’s A3 negative outlook, S&P BBB+ CreditWatch negative and Fitch A- stable. The Solventum separation creates transition, indemnity, tax-treatment, supply and potential dis-synergy risks; 3M is also less diversified after the separation. Other disclosed risks include foreign exchange, market demand, raw-material and supply-chain disruptions, cyber incidents and litigation outcomes.

Most important facts for investors to verify

  1. How the Solventum separation, retained 19.9% stake and approximately $7.7 billion of expected proceeds affect 3M’s post-separation cash, debt, continuing earnings and liquidity.
  2. Actual timing and cash payments under the PWS and Combat Arms settlements, including settlement conditions, appeals or challenges, and whether accruals remain adequate.
  3. Future PFAS remediation, regulatory and litigation exposure beyond the $11.1 billion environmental accrual; 3M says excess loss cannot currently be estimated.
  4. Whether Q1 margin improvement and adjusted EPS gains persist after the timing benefits from stock-based compensation and the effects of special items.
  5. Progress and costs for restructuring and the 2025 PFAS exit, including operational impacts from permits, substitutes and customer requalification.